Ablashi, D V, Levine, P H, De Vinci, C et al. · Biotherapy (Dordrecht, Netherlands) · 1996 · DOI
This small study tested whether a special immune treatment called transfer factor, designed to target HHV-6 (a virus that may be active in some ME/CFS patients), could help. Two ME/CFS patients with active HHV-6 infection received this treatment. One patient improved significantly and returned to normal activities within weeks, but the other patient saw no improvement. The results suggest this treatment might help control HHV-6 in some patients, but more research is needed.
Since HHV-6 reactivation has been proposed as a potential contributor to ME/CFS pathology in some patients, this study explores whether targeting the virus could improve symptoms. The marked clinical improvement in one patient suggests that virus-specific immune treatments warrant further investigation as a potential therapeutic strategy for a subset of ME/CFS patients.
This study does not prove that HHV-6 causes ME/CFS, only that it may be active in some patients with the condition. The divergent outcomes in just two patients prevent any conclusions about how often this treatment works or who might benefit. The lack of a control group means we cannot determine whether improvement was due to the transfer factor or other factors.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.